Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBarr (A.G.) Regulatory News (BAG)

Share Price Information for Barr (A.G.) (BAG)

Share Price is delayed by 15 minutes
Get Live Data
618.00    5.00 (0.82%)
Bid:
617.00
Ask:
619.00
Spread: 2.00 (0.324%)
Market Cap: £685.83m
BAG Live PriceLast checked at - London Stock Exchange

Intraday Barr (A.G.) Share Chart

Trading Statement

30 Jul 2024 07:00

RNS Number : 2803Y
Barr(A.G.) PLC
30 July 2024
 

 IMMEDIATE RELEASE 30 July 2024

A.G. BARR p.l.c.

("A.G. BARR" or "the business")

 

Strong Revenue Growth And Margin Rebuild On Track

A.G. BARR p.l.c., the branded multi-beverage business with a portfolio of market-leading UK brands, today announces a trading update for the 26 weeks ended 27 July 2024.

Headlines

- A.G. BARR: H1 revenue growth of c.5% of which Soft Drinks growth was c.7%

- IRN-BRU: growth in volume and value supported by a highly successful Euros media campaign

- Rubicon: double digit growth with innovation, marketing investment and new distribution gains

- Boost: margin realignment and business integration on plan, production sourcing programme underway

Euan Sutherland, Chief Executive, commented:

"I am pleased to report overall H1 revenue growth of c.5% with Soft Drinks growth of c.7%, against strong prior year comparatives. The strategic margin rebuild programmes are on plan, guidance on revenue and margin remains unchanged, and we are on track to meet FY expectations*.

Our four power brands - IRN-BRU, Rubicon, Boost and FUNKIN - have clear paths to long term growth, supported by strong innovation programmes across all of our portfolio and opportunities to work even more closely to add value to our customers, in all channels.

We continue to invest in our supply chain which will deliver tangible benefits as we insource more of our volume, build capacity to support our growth plans, improve resilience and enhance our margins.

We have a clear and focussed UK based growth strategy with simple KPIs of Net Revenue, Operating Margin and ROCE."

Performance Highlights

Revenue for the first half of the financial year is expected to be c.£221m (2023/24 : £210.4m).

Soft Drinks

Strong Soft Drinks brand performance was led by Rubicon where successful marketing and further distribution gains drove double digit revenue growth. Revenue from IRN-BRU was up through a combination of volume and value growth and continued market share gains in England. As previously communicated, the focus for Boost this year is on margin build and insourcing of the operation and this continues on plan. 

Cocktail Solutions

The FUNKIN ready-to-drink (RTD) business has continued to grow at pace in our strategic growth channel of retail where it is the number 1 RTD cocktail brand. Strong off-trade growth was impacted by short term issues with third party can production and the ongoing challenges in the hospitality sector where late night venues remain particularly affected.

Other and Business Change Programme

MOMA maintained its growth in H1 with new distribution gains.

The Barr Direct route to market closed at the end of June with no impact to customer service. Symbol and Independent retailers are now fully serviced through the Wholesale Channel, supported by a larger Field Sales team.

The integration of Boost into Barr Soft Drinks is on track and will be completed in H2. Manufacturing synergies continue to be realised as production is insourced.

As previously stated, these two projects are expected to give rise to a one-off cost of c.£5m in the 2024/25 financial year, the majority of which will be incurred in H1. 

As previously communicated, Jonathan Kemp, Commercial Director, will retire later in the year and we are pleased to announce the appointment of Dino Labbate**. Dino joins in January, in a newly created, broader role of MD A.G. BARR, reporting to Euan Sutherland. Jonathan will not be replaced on the board and will remain with the business on a consultancy basis through to autumn 2025.

H2 Outlook

The half year trading performance is in line with our expectations. We remain committed to improving our profit margins which, combined with the forecast revenue growth, will lead to positive earnings momentum for H2 and beyond. The outlook for the full year remains unchanged and we are on track to meet FY expectations*.

For more information, please contact :

A.G. BARR Instinctif Partners

0330 390 3900 020 7457 2010/05

Euan Sutherland, Chief Executive Justine Warren

Stuart Lorimer, Finance Director Matthew Smallwood

 

 

* Analyst consensus : FY24 Net Revenue £421.2m, PBT £56.9m (FY23 PBT £50.5m)

** Dino Labbate is currently GB Commercial Director for Hospitality, Britvic PLC

 

Next update : Interim Results - 24 September 2024

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTUKSNRSVUBUAR
Date   Source Headline
9th Apr 202511:23 amRNSDirector/PDMR Shareholding
8th Apr 20253:29 pmRNSDirector/PDMR Shareholding
25th Mar 20257:00 amRNSResults for year ended 25 January 2025
10th Mar 20252:04 pmRNSDirector/PDMR Shareholding
10th Feb 20253:59 pmRNSDirector/PDMR Shareholding - Replacement
10th Feb 20253:10 pmRNSDirector/PDMR Shareholding
28th Jan 20257:00 amRNSTrading Update
20th Jan 202511:00 amRNSDirector Declaration
9th Jan 20254:42 pmRNSDirector/PDMR Shareholding
7th Jan 202511:44 amRNSNotice of Trading Update
17th Dec 20249:20 amRNSDirector Declaration
9th Dec 20241:50 pmRNSDirector/PDMR Shareholding
12th Nov 20241:35 pmRNSDirector/PDMR Shareholding
4th Nov 202410:54 amRNSDirector/PDMR Shareholding
9th Oct 202410:10 amRNSDirector/PDMR Shareholding
24th Sep 20247:00 amRNSInterim Results
9th Sep 20241:03 pmRNSDirector/PDMR Shareholding
4th Sep 20249:08 amRNSDirector Declaration
20th Aug 20248:39 amRNSDirector/PDMR Shareholding
8th Aug 20241:10 pmRNSDirector/PDMR Shareholding
30th Jul 20247:00 amRNSTrading Statement
8th Jul 202412:03 pmRNSDirector/PDMR Shareholding
4th Jul 202410:17 amRNSNotice of Results
1st Jul 20244:50 pmRNSDirector/PDMR Shareholding
21st Jun 20243:22 pmRNSDirector/PDMR Shareholding
10th Jun 20241:51 pmRNSDirector/PDMR Shareholding
10th Jun 20241:48 pmRNSDirector/PDMR Shareholding
4th Jun 20249:36 amRNSDirector/PDMR Shareholding
31st May 20241:54 pmRNSResult of AGM
9th May 202411:28 amRNSDirector/PDMR Shareholding
7th May 20249:06 amRNSDirector/PDMR Shareholding
23rd Apr 20249:17 amRNSAnnual Financial Report
15th Apr 20242:59 pmRNSDirector/PDMR Shareholding
9th Apr 20243:46 pmRNSDirector/PDMR Shareholding - replacement
9th Apr 20243:36 pmRNSDirector/PDMR Shareholding
9th Apr 20241:05 pmRNSDirector/PDMR Shareholding - replacement
9th Apr 202412:50 pmRNSDirector/PDMR Shareholding
5th Apr 20242:26 pmRNSDirector/PDMR Shareholding
2nd Apr 202411:15 amRNSDirector/PDMR Shareholding
28th Mar 202410:10 amRNSDirector/PDMR Shareholding
26th Mar 20247:00 amRNSDirectorate changes announcement
26th Mar 20247:00 amRNSFinal Results
14th Mar 20243:01 pmRNSBusiness reorganisation
11th Mar 20248:39 amRNSDirector/PDMR Shareholding
27th Feb 20241:47 pmRNSHolding(s) in Company
8th Feb 20242:03 pmRNSDirector/PDMR Shareholding - Replacement
8th Feb 20241:51 pmRNSDirector/PDMR Shareholding
1st Feb 20247:00 amRNSBoard succession announcement
1st Feb 20247:00 amRNSTrading Update
16th Jan 20247:00 amRNSNotice of Trading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.